

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate reduction in the risk of disease progression or death with belantamab mafodotin with bortezomib/dexamethasone versus daratumumab/bortezomib/dexamethasone for patients with previously treated multiple myeloma (MM) in the DREAMM-7 trial?
 - a. 12%
 - b. 22%
 - c. 32%
 - d. 42%
2. The Phase III DEAMM-10 trial is evaluating belantamab mafodotin in combination with lenalidomide/dexamethasone versus daratumumab/lenalidomide/dexamethasone in which of the following settings?
 - a. Newly diagnosed transplant-ineligible MM
 - b. Relapsed/refractory (R/R) MM after at least one prior line of therapy
 - c. Triple-class refractory MM
3. What was the approximate 12-month overall survival rate with anitocabtagene autoleucel in the Phase II iMMagine-1 trial for patients with R/R MM?
 - a. 66.5%
 - b. 76.5%
 - c. 86.5%
 - d. 96.5%
4. In a single-center study evaluating tocilizumab prophylaxis for patients receiving a bispecific antibody for R/R MM, what was the approximate rate of cytokine release syndrome?
 - a. 4%
 - b. 14%
 - c. 34%
 - d. 54%
5. What was the approximate overall minimal residual disease-negativity rate (10^{-5}) with daratumumab/bortezomib/lenalidomide/dexamethasone for transplant-ineligible patients with newly diagnosed MM in the Phase III CEPHEUS trial?
 - a. 30%
 - b. 46%
 - c. 61%
 - d. 90%